There is no reason to suppose that any of CTIX's drugs are
There is no reason to suppose that any of CTIX's drugs are going to fail, given the fact that the company has stated that so far they have had 100% success rate with clinical trials, and the fact that the Bril-UP trial was announced AFTER the company had seen what was going on within the Bril-OM trial. There was quite a discussion about the fact that the company DOES get to review raw data, even in a double-blinded study. It is entirely reasonable to assume that Brilacidin-OM results could be extrapolated, given the high percentage of patients who develop oral mucositis. A significant decrease in those numbers by the patient cohort would be indicative of success whether or not it's known which patients got placebo. The fact that the company also changed their wording to flat-out state that it "exhibited anti-inflammatory activity" (whatever the exact wording was) also indicates that they had seen something in the OM trials that allowed them to make that statement. Taken in conjunction with their commencement of the Bril-UP trial based on that, it seems reasonable to assume that at least Bril-OM is headed down the right pathway. Because the UP is significantly behind the OM trial in timeline, and because the company is adding more sites to the OM trial to speed up recruitment, it's reasonable to think that the Bril-OM trial will have at least interim results to post before the Bril-UP trial does. Since we're dealing in hypotheticals here, what if the Bril-OM trial is a success (as seems likely now) and then (in the scenario that is ONLY hypothetical) the Bril-UP trial fails? Well, CTIX will have gone to a much higher stock price on the basis of the Bril-OM trial, so who knows?
And that's the answer to your question. What happens if a drug fails? Who knows, because we don't know what OTHER drug trials may have caused the stock price to rise before the hypothetical failure.
And your premise is false. Brilacidin-UP is NOT "front and center."
When a new poster appears with several posts that look like they could be soft bashing, and then starts a post with "what if a drug fails" -- on a day when the stock is already being attacked -- I think you can understand why people are curious about whether you are being disingenuous. I hope that is not the case.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...
Continue Reading
Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...
Continue Reading
Gildan Investors, Brace Yourself Poor old Gildan Activewear finds itself in hot water again, with a class action lawsuit cropping up like an unexpected storm on farmers' day. Any traders remotely involved with NYSE:GIL should pay damn close attention, because with a December 14, 2026 deadline looming, it's crunch time. The Root of the Lawsuit The plot thickens here,...
Continue Reading
Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...
Continue Reading
Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...
Continue Reading
NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...
Continue Reading
Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...
Continue Reading
China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...
Continue Reading
The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....
Continue Reading
Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...
Continue Reading
Top 5 Most Recently Viewed Articles
A New Era for IT Management Trying to keep tabs on the ever-growing jungle of software and AI is like herding cats these days. BetterCloud, a leader in SaaS management, just rolled out an AI-native platform to throw its hat in the ring and tackle this wild frontier. They're promising enterprises a fighting chance against the chaos with a tool that bundles AI governance,...
Continue Reading
Senvest Capital Inc. Announces Acceptance of Buyback Program Senvest Capital Inc. (TSX: SEC) has received a green light from the Toronto Stock Exchange (TSX) to proceed with its plan for a normal course issuer bid (NCIB). The decision allows the corporation to buy back up to 100,000 of its common shares, amounting to about 4.12% of its total outstanding shares. This...
Continue Reading
Revolutionizing Salon Experiences With a New Chair Design Every hairstylist knows the importance of comfort and accessibility in a salon environment. After 33 years of experience in hairstyling, one innovative stylist envisioned a solution to improve the salon chair, resulting in the development of THE SALON CHAIR. This invention enhances client safety, particularly for...
Continue Reading
Magnera's Participation at the 2025 Wells Fargo Conference In a notable announcement from Magnera Corporation (NYSE: MAGN), the company revealed its plans to attend the highly anticipated 2025 Wells Fargo Industrials & Materials Conference. This event is set to take place in Chicago, bringing together industry leaders and innovators from around the globe. Leadership...
Continue Reading
Walmart's Impressive Third-Quarter Earnings Walmart Inc. (NYSE: WMT) has once again exceeded the expectations of market analysts with a remarkable performance in its latest earnings report. The retail giant reported adjusted earnings per share of 62 cents, surpassing the market consensus of 60 cents. Initially, the stock dipped by 2.5% in response to the earnings release...
Continue Reading